Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kari Remes

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
European Journal of Haematology|June 16, 2010
ETS-related gene ERG expression in AML patients is significantly associated with NPM1 mutation statusMauri Hämäläinen, Vesa Juvonen, Satu Häikiö, et al.
European Journal of Haematology|April 16, 2008
Stem cell transplantation in poor-risk chronic lymphocytic leukemia: assessment of post-transplant minimal residual disease using four- and six-color flow cytometry and allele-specific RQ-PCRMaija Itälä, Anna-Riina Huhtinen, Vesa Juvonen, et al.
Journal of Patient-Reported Outcomes|February 5, 2024
Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic Myeloma Study GroupLene Kongsgaard Nielsen, Fredrik Schjesvold, Sören Möller, et al.
European Journal of Haematology|December 18, 2007
Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemiaMauri M Hämäläinen, Veli Kairisto, Vesa Juvonen, et al.
Annals of Hematology|August 4, 2016
Cost analysis of a randomized stem cell mobilization study in multiple myelomaVille Varmavuo, Raija Silvennoinen, Pekka Anttila, et al.
Medical Oncology (Northwood, London, England)|January 12, 2011
BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?Franz X Gruber, Tuija Lundán, Rasmus Goll, et al.
Transfusion|April 5, 2016
Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparisonJaakko Valtola, Raija Silvennoinen, Antti Ropponen, et al.
Duodecim; Laaketieteellinen Aikakauskirja|November 23, 2005
[Directions for allogenic stem cell transplants and how they reflect on the operation and results of the transfer center in Turku]Kari Remes, Sini Luoma, Toivo T Salmi, et al.
European Journal of Haematology|December 31, 2013
Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular responsePerttu Koskenvesa, Anna Kreutzman, Peter Rohon, et al.
European Journal of Haematology|March 30, 2007
Long-term outcome of intensive chemotherapy for adults with de novo acute myeloid leukaemia (AML): the nationwide AML-92 study by the Finnish Leukaemia GroupPirjo Koistinen, Riikka Räty, Maija Itälä, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
European Journal of Haematology|June 16, 2010
ETS-related gene ERG expression in AML patients is significantly associated with NPM1 mutation statusMauri Hämäläinen, Vesa Juvonen, Satu Häikiö, et al.
European Journal of Haematology|April 16, 2008
Stem cell transplantation in poor-risk chronic lymphocytic leukemia: assessment of post-transplant minimal residual disease using four- and six-color flow cytometry and allele-specific RQ-PCRMaija Itälä, Anna-Riina Huhtinen, Vesa Juvonen, et al.
Journal of Patient-Reported Outcomes|February 5, 2024
Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic Myeloma Study GroupLene Kongsgaard Nielsen, Fredrik Schjesvold, Sören Möller, et al.
European Journal of Haematology|December 18, 2007
Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemiaMauri M Hämäläinen, Veli Kairisto, Vesa Juvonen, et al.
Annals of Hematology|August 4, 2016
Cost analysis of a randomized stem cell mobilization study in multiple myelomaVille Varmavuo, Raija Silvennoinen, Pekka Anttila, et al.
Medical Oncology (Northwood, London, England)|January 12, 2011
BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?Franz X Gruber, Tuija Lundán, Rasmus Goll, et al.
Transfusion|April 5, 2016
Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparisonJaakko Valtola, Raija Silvennoinen, Antti Ropponen, et al.
Duodecim; Laaketieteellinen Aikakauskirja|November 23, 2005
[Directions for allogenic stem cell transplants and how they reflect on the operation and results of the transfer center in Turku]Kari Remes, Sini Luoma, Toivo T Salmi, et al.
European Journal of Haematology|December 31, 2013
Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular responsePerttu Koskenvesa, Anna Kreutzman, Peter Rohon, et al.
European Journal of Haematology|March 30, 2007
Long-term outcome of intensive chemotherapy for adults with de novo acute myeloid leukaemia (AML): the nationwide AML-92 study by the Finnish Leukaemia GroupPirjo Koistinen, Riikka Räty, Maija Itälä, et al.
Pageof 4